Top

Published in:

01-12-2014 | Head and Neck Oncology

The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients

Authors: Li-Han Lin, MS, Ming-Wei Lin, PhD, Kwei Mar, DDS, Chun-Shu Lin, MD, Dar-Der Ji, PhD, Wei-Ping Lee, MD, PhD, Herng-Sheng Lee, MD, PhD, Ming-Fang Cheng, MD, Kan-Tai Hsia, DDS, PhD

Published in: Annals of Surgical Oncology | Issue 13/2014

Abstract

Background

The aim of this study was to investigate the impact of hMLH1 polymorphisms on treatment outcomes in patients with oral squamous cell carcinoma (OSCC).

Methods

Genotypings were performed by direct DNA sequencing in peripheral blood leukocytes from 185 male OSCC patients. Patients received primary surgery with or without adjuvant radiotherapy. Two hMLH1 tag single nucleotide polymorphisms (SNPs)—rs1800734 (−93G>A in the promoter) and rs1540354 (in the third intron)—were chosen from the HapMap project. Overall survival (OS) and disease-free survival (DFS) were compared between different genotypes.

Results

The hMLH1 rs1800734 and rs1540354 polymorphisms were in weak linkage disequilibrium (r ² = 0.456). OSCC patients with the rs1800734 AA genotype had a significantly poor prognosis in both OS and DFS. This SNP can also predict the outcomes of OSCC patients with postoperative adjuvant radiotherapy, especially in advanced stage; however, no significant differences in patient outcomes were found for the hMLH1 rs1540354 genotypes.

Conclusions

Our results demonstrate that the hMLH1 −93G>A SNP is found to be associated with patient outcomes in OSCC. This SNP can also predict their treatment outcome of radiotherapy.

Available only for authorised users

Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009;15:388–399.PubMedCrossRef

Department of Health, Executive Yuan, Taiwan, ROC. Cancer registry annual report in Taiwan area. Department of Health; 2012.

Kademani D, Bell RB, Bagheri S, et al. Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg. 2005;63:1599–1605.PubMedCrossRef

da Silva SD, Ferlito A, Takes RP, et al. Advances and applications of oral cancer basic research. Oral Oncol. 2011;47:783–791.PubMedCrossRef

Shah JP, Gil Z. Current concepts in management of oral cancer: surgery. Oral Oncol. 2009;45:394–401.PubMedCentralPubMedCrossRef

Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000;36:256–263.PubMedCrossRef

Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7:335–346.PubMedCrossRef

Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev. 2008;129:391–407.PubMedCentralPubMedCrossRef

Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008;29:673–680.PubMedCrossRef

10.

Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene. 2003;22:2352–2360.PubMedCrossRef

11.

Murata H, Khattar NH, Kang Y, Gu L, Li GM. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene. 2002;21:5696–5703.PubMedCrossRef

12.

Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology. 2005;129:537–549.PubMed

13.

Bannister LA, Waldman BC, Waldman AS. Modulation of error-prone double-strand break repair in mammalian chromosomes by DNA mismatch repair protein Mlh1. DNA Repair (Amst). 2004;3:465–474.PubMedCrossRef

14.

Zhang Y, Rohde LH, Emami K, et al. Suppressed expression of non-DSB repair genes inhibits gamma-radiation-induced cytogenetic repair and cell cycle arrest. DNA Repair (Amst). 2008;7:1835–1845.PubMedCrossRef

15.

Yan T, Seo Y, Kinsella TJ. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells. Clin Cancer Res. 2009;15:6912–6920.PubMedCentralPubMedCrossRef

16.

Lipkin SM, Rozek LS, Rennert G, et al. The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet. 2004;36:694–699.PubMedCrossRef

17.

Allan JM, Shorto J, Adlard J, et al. MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer. 2008;123:2456–2459.PubMedCrossRef

18.

Mrkonjic M, Roslin NM, Greenwood CM, et al. Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer. PLoS One. 2010;5(10):e13314.PubMedCentralPubMedCrossRef

19.

Chen H, Taylor NP, Sotamaa KM, et al. Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer. 2007;120:1684–1688.PubMedCrossRef

20.

Samowitz WS, Curtin K, Wolff RK, et al. The MLH1 −93G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosomes Cancer. 2008;47:835–844.PubMedCentralPubMedCrossRef

21.

Shih CM, Chen CY, Lee IH, Kao WT, Wang YC. A polymorphism in the hMLH1 gene (−93G>A) associated with lung cancer susceptibility and prognosis. Int J Mol Med. 2010;25:165–170.PubMed

22.

Edge SB, American joint committee on cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

23.

Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. 1987;95:229–249.PubMed

24.

Huang SH, Chang PY, Liu CJ, Lin MW, Hsia KT. O6-methylguanine-DNA methyltransferase gene coding region polymorphisms and oral cancer risk. J Oral Pathol Med. 2010;39:645–650.PubMedCrossRef

25.

Zhao JH. 2LD, GENECOUNTING and HAP: Computer programs for linkage disequilibrium analysis. Bioinformatics. 2004;20:1325–1326.PubMedCrossRef

26.

Raptis S, Mrkonjic M, Green RC, et al. MLH1 −93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 2007;99:463–474.PubMedCrossRef

27.

Whiffin N, Broderick P, Lubbe SJ, et al. MLH1−93G>A is a risk factor for MSI colorectal cancer. Carcinogenesis. 2011;32:1157–1161.PubMedCrossRef

28.

Czerninski R, Krichevsky S, Ashhab Y, Gazit D, Patel V, Ben-Yehuda D. Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. Oral Dis. 2009;15:206–213.PubMedCrossRef

29.

Gonzalez-Ramirez I, Ramirez-Amador V, Irigoyen-Camacho ME, et al. hMLH1 promoter methylation is an early event in oral cancer. Oral Oncol. 2011;47:22–26.PubMedCrossRef

30.

Arita M, Zhong X, Min Z, Hemmi H, Shimatake H. Multiple sites required for expression in 5′-flanking region of the hMLH1 gene. Gene. 2003;306:57–65.PubMedCrossRef

31.

Mei M, Liu D, Dong S, Ingvarsson S, Goodfellow PJ, Chen H. The MLH1 −93G promoter variant influences gene expression. Cancer Epidemiol. 2010;34:93–95.PubMedCrossRef

32.

Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–316.PubMedCrossRef

33.

Sanguansin S, Petmitr S, Punyarit P, Vorasubin V, Weerapradist W, Surarit R. HMSH2 gene alterations associated with recurrence of oral squamous cell carcinoma. J Exp Clin Cancer Res. 2006;25:251–257.PubMed

34.

Lo YL, Hsiao CF, Jou YS, et al. Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer. 2010;72:280–286.PubMedCrossRef

35.

Park SH, Lee GY, Jeon HS, et al. −93G>A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer. 2004;112:678–682.PubMedCrossRef

Title: The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients
Authors: Li-Han Lin, MS
Ming-Wei Lin, PhD
Kwei Mar, DDS
Chun-Shu Lin, MD
Dar-Der Ji, PhD
Wei-Ping Lee, MD, PhD
Herng-Sheng Lee, MD, PhD
Ming-Fang Cheng, MD
Kan-Tai Hsia, DDS, PhD
Publication date: 01-12-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 13/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3897-x

At a glance: The STEP trials

Springer Medicine

The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2014

Can Breast Surgeons Provide Breast Cancer Genetic Testing? An American Society of Breast Surgeons Survey

Surgical Management of Bone Metastases: Quality of Evidence and Systematic Review

Predictive Factors and Pattern of Locoregional Recurrence After Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma

Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients

Centralization of Esophagectomy: How Far Should We Go?

Rate of Contralateral Prophylactic Mastectomy is Influenced by Preoperative MRI Recommendations